20:56 , Jul 2, 2018 |  BC Extra  |  Company News

Dunsire to become Lundbeck CEO

Neurology company H. Lundbeck A/S (CSE:LUN) hired Deborah Dunsire as president and CEO, effective Sept. 1. Dunsire will fill a position that became vacant when Kåre Schultz resigned in September 2017. CFO Anders Götzsche has been...
03:05 , Jun 30, 2018 |  BioCentury  |  Finance

Hidden in the rough

Judicious stock picking was especially important in the second quarter, as 57% of global biotech stocks saw their equity values decline. Volatility continued to roil global markets during the period and additional uncertainty looms with the...
03:04 , Jun 30, 2018 |  BioCentury  |  Finance

Eyes on launches

The annual summer slowdown isn’t restricted to just the stock market this year, as the clinical catalyst calendar also appears to be on holiday in 3Q18. Buysiders are therefore turning their attention to a spate of...
18:26 , Jun 22, 2018 |  BC Week In Review  |  Clinical News

Teva discontinues Phase III chronic cluster headache trial of fremanezumab

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; Tel Aviv:TEVA) discontinued a Phase III trial of fremanezumab (TEV-48125) to prevent chronic cluster headache based on a prespecified futility analysis. The company said a Phase III trial of the...
19:59 , Jun 15, 2018 |  BC Week In Review  |  Company News

ICER panel says long-term value for Aimovig for migraines is intermediate

ICER's California Technology Assessment Forum (CTAF) voted that the long-term value of calcitonin gene-related peptide (CGRP) inhibitor Aimovig erenumab for patients with chronic migraine who had previously failed other preventative migraine treatments was intermediate, while...
19:07 , Jun 15, 2018 |  BC Extra  |  Clinical News

Teva discontinues chronic cluster headache trial of fremanezumab

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; Tel Aviv:TEVA) discontinued a Phase III trial of fremanezumab (TEV-48125) to prevent chronic cluster headache based on a prespecified futility analysis. The company said a Phase III trial of the...
20:40 , Jun 14, 2018 |  BC Week In Review  |  Clinical News

Allergan's atogepant meets in Phase IIb/III to prevent migraine

Allergan plc (NYSE:AGN) said all doses of oral atogepant (MK-8031) met the primary endpoint in the double-blind, U.S. Phase IIb/III CGP-MD-01 trial to prevent episodic migraine. The company declined to disclose next steps for the...
21:23 , Jun 11, 2018 |  BC Extra  |  Clinical News

Allergan's atogepant meets in Phase IIb/III to prevent migraine

Allergan plc (NYSE:AGN) said all doses of oral atogepant (MK-8031) met the primary endpoint in the Phase IIb/III CGP-MD-01 trial to prevent episodic migraine. The company declined to disclose next steps for the small molecule...
18:23 , Jun 8, 2018 |  BC Week In Review  |  Clinical News

FDA rebuffs third biosimilar Herceptin

Amgen Inc. (NASDAQ:AMGN) received a complete response letter from FDA for ABP 980. This marks the third CRL the agency has issued for a biosimilar of Herceptin trastuzumab. Amgen declined to disclose details of the...
23:11 , Jun 7, 2018 |  BC Week In Review  |  Company News

ICER updates cost-effectiveness estimates for CGRP inhibitors for migraines

ICER released an evidence report May 31 evaluating calcitonin gene-related peptide (CGRP) inhibitors for migraine prevention that calculated more favorable long-term cost-effectiveness ratios than in its April draft evidence report. ICER updated the cost-effectiveness analyses...